Investinor

Investinor is a Norwegian state-backed investor headquartered in Trondheim that aggressively co-invests to scale domestic marine biotech, software, and medical technology companies. The firm’s mandate is closely tied to Norwegian industrial development, which means capital flows toward companies with substantial Norwegian presence or strategic relevance to the country’s industrial base. Healthcare interest is concentrated in medical devices and biotech, areas where Norway has notable scientific assets and where Investinor’s role as a co-investor can support international scaling. AI is not a stated focus.

Investinor invests at Series B, Series C, and Growth stages with checks of $1M to $5M when participating in syndicates. The check size relative to the stage range indicates that Investinor typically takes a co-investor position alongside larger lead investors rather than acting as a primary anchor. The geographic emphasis is Norway, with the firm’s mandate to strengthen domestic industry shaping which companies are eligible. Founders should expect a process that combines conventional investor diligence with attention to the public mission and mandate that informs Investinor’s decisions.

Named partners and specific portfolio companies are not detailed in the materials reviewed, so this profile reflects limited public information about the team and named investments. Founders considering Investinor should prepare a clear case for the company’s relevance to the Norwegian innovation ecosystem, a credible international growth plan, and an articulated role for a state-backed co-investor within a broader syndicate. The most productive first conversation explains the lead investor context, the company’s commercial inflection point, and how Investinor’s participation strengthens both Norwegian impact and the company’s competitive position internationally.